Shinsuke Iida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinsuke Iida has a total of 880 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Ishida
Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
24 shared publications - Masaki Ri
Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan
23 shared publications Hirokazu Komatsu
Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan
19 shared publicationsShigeru Kusumoto
Nagoya City University Graduate School of Medical Sciences
17 shared publicationsRyuzo Ueda
Department of Tumor Immunology School of Medicine Aichi Medical University Nagakute Japan
16 shared publicationsAsahi Ito
Nagoya City University, Nagoya, Japan
15 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Wiley in Cancer Science
Cardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma
Although immunotherapies have improved outcomes in multiple myeloma (MM), therapeutic resistance remains a major challenge, thereby underscoring the need for strategies that enhance tumor immunogenicity. Here, we show that cardiac glycosides (CGs), including periplocin and digoxin, act as immunogenic sensitizers in MM. CG treatment upregulated the cell‐surface expression of ICAM‐1, 4‐1BBL, and SLAMF7 in MM cell lines and primary patient‐derived CD138 + cells. Mechanistically, our findings support the involvement of Na + /K + ‐ATPase inhibition, Ca 2+ signaling, and mitochondrial‐ and endoplasmic reticulum (ER)‐associated ROS pathways in CG‐induced immune remodeling. CGs also induced immunogenic cell death (ICD)‐associated changes, including cell‐surface calreticulin exposure and extracellular HMGB1 and ATP release. These changes were associated with ferroptosis, as indicated by intracellular Fe 2+ accumulation, lipid peroxidation, elevated malondialdehyde levels, and attenuation of ICD markers by ferroptosis inhibitors. Functionally, CG treatment enhanced the cytotoxic effects of elotuzumab and teclistamab by promoting effector T‐ and NK‐cell‐mediated killing. Collectively, our findings suggest that the Na + /K + ‐ATPase–Ca 2+ –ROS axis contributes to immune remodeling and ferroptosis‐associated ICD in MM. These results provide mechanistic insights into stress‐induced tumor immunogenicity and support further investigation of CGs as sensitizers for antibody‐based immunotherapy in MM.
- 17 November 2026
- Published by Wiley in Cancer Science
Open AccessCardiac Glycosides Drive Immune Remodeling and Ferroptosis‐Associated Immunogenic Cell Death in Multiple Myeloma
Although immunotherapies have improved outcomes in multiple myeloma (MM), therapeutic resistance remains a major challenge, thereby underscoring the need for strategies that enhance tumor immunogenicity. Here, we show that cardiac glycosides (CGs), including periplocin and digoxin, act as immunogenic sensitizers in MM. CG treatment upregulated the cell‐surface expression of ICAM‐1, 4‐1BBL, and SLAMF7 in MM cell lines and primary patient‐derived CD138 + cells. Mechanistically, our findings support the involvement of Na + /K + ‐ATPase inhibition, Ca 2+ signaling, and mitochondrial‐ and endoplasmic reticulum (ER)‐associated ROS pathways in CG‐induced immune remodeling. CGs also induced immunogenic cell death (ICD)‐associated changes, including cell‐surface calreticulin exposure and extracellular HMGB1 and ATP release. These changes were associated with ferroptosis, as indicated by intracellular Fe 2+ accumulation, lipid peroxidation, elevated malondialdehyde levels, and attenuation of ICD markers by ferroptosis inhibitors. Functionally, CG treatment enhanced the cytotoxic effects of elotuzumab and teclistamab by promoting effector T‐ and NK‐cell‐mediated killing. Collectively, our findings suggest that the Na + /K + ‐ATPase–Ca 2+ –ROS axis contributes to immune remodeling and ferroptosis‐associated ICD in MM. These results provide mechanistic insights into stress‐induced tumor immunogenicity and support further investigation of CGs as sensitizers for antibody‐based immunotherapy in MM.
- Open Access
- 11 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
- 11 November 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessReal-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
- Open Access
- 15 October 2026
- Published by Wiley in Cancer Science
Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH ‐ MM ‐15 Study
T(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associated with other cytogenetic risk categories. In a post hoc analysis of the prospective JSH‐MM‐15 study, we investigated the prognosis of newly diagnosed MM patients to identify prognostic features unique to t(11;14)‐positive cases and to evaluate treatment factors influencing outcomes. Among 482 patients evaluated for t(11;14), 131 (27%) were positive. Overall survival (OS) in t(11;14)‐positive patients was intermediate between standard‐ and high‐risk groups, whereas progression‐free survival (PFS) was comparable to that of high‐risk cases. Deep response rates, including ≥ complete response (CR)/stringent CR and ≥ very good partial response, were lower in t(11;14)‐positive MM than in other risk groups, and these responses were not associated with survival in t(11;14)‐positive cases, in contrast to t(11;14)‐negative MM. Compared with t(11;14)‐negative MM, t(11;14)‐positive patients more frequently expressed CD20 and less frequently expressed CD56 on myeloma cells. Exploratory analyses showed that, despite higher ≥ CR rates, OS was worse in patients with CD20‐negative/CD56‐negative tumors among t(11;14)‐positive MM. Among CD20‐positive patients, PI‐containing regimens were associated with better OS, although no significant PFS benefit was observed. These findings support the biological and clinical heterogeneity of t(11;14)‐positive MM and highlight the need for prospective validation of subgroup‐specific treatment outcomes.
- 15 October 2026
- Published by Wiley in Cancer Science
Open AccessDistinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH ‐ MM ‐15 Study
T(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associated with other cytogenetic risk categories. In a post hoc analysis of the prospective JSH‐MM‐15 study, we investigated the prognosis of newly diagnosed MM patients to identify prognostic features unique to t(11;14)‐positive cases and to evaluate treatment factors influencing outcomes. Among 482 patients evaluated for t(11;14), 131 (27%) were positive. Overall survival (OS) in t(11;14)‐positive patients was intermediate between standard‐ and high‐risk groups, whereas progression‐free survival (PFS) was comparable to that of high‐risk cases. Deep response rates, including ≥ complete response (CR)/stringent CR and ≥ very good partial response, were lower in t(11;14)‐positive MM than in other risk groups, and these responses were not associated with survival in t(11;14)‐positive cases, in contrast to t(11;14)‐negative MM. Compared with t(11;14)‐negative MM, t(11;14)‐positive patients more frequently expressed CD20 and less frequently expressed CD56 on myeloma cells. Exploratory analyses showed that, despite higher ≥ CR rates, OS was worse in patients with CD20‐negative/CD56‐negative tumors among t(11;14)‐positive MM. Among CD20‐positive patients, PI‐containing regimens were associated with better OS, although no significant PFS benefit was observed. These findings support the biological and clinical heterogeneity of t(11;14)‐positive MM and highlight the need for prospective validation of subgroup‐specific treatment outcomes.
- Top Cited PapersOpen Access
- 20 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (6) , 466-475
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)–assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)–assessed PFS, safety, and tolerability. RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)–related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
- 20 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (6) , 466-475
Top Cited PapersOpen AccessBRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)–assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)–assessed PFS, safety, and tolerability. RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)–related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
- Open Access
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e75586
Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database
Background: With the availability of newer therapies, the duration of therapy (DoT) shortens with each increasing line of treatment in Japanese patients with multiple myeloma (MM). Objective: This study aimed to identify factors that shorten DoT in patients with MM using a machine learning (ML) procedure from the Medical Data Vision (MDV) database. Methods: This nationwide, retrospective observational real-world study was conducted using anonymized patient data from the MDV claims database from 2003 to 2022. Patients (≥18 y) with transplant-ineligible newly diagnosed MM (continued first line therapy), or relapsed or refractory MM (continued second or third line therapies) were included. To identify important predictive factors, an explainable deep learning model was created using 647 extracted variables (continuous, binary, and nominal categorical) from the MDV database, and the extracted data were used to train ML algorithms to build point-wise linear (PWL) models for predicting DoT. Predictive performance of the PWL model was compared with the elastic net (regularized logistic regression) and the extreme gradient boosting models, and calculated by area under the curve and evaluated by 10-fold double cross-validation. A clustering analysis (k-means method) of 4848 individual samples assessed the relationship between each sample and DoT (3, 6, and 12 months). The characteristics of clusters and sample features belonging to each cluster during and after treatment were studied. Results: Overall, 2762 (4848 individual samples) patients were evaluated (mean age 69.6, SD 11.8 years; 1450/2762, 52.5% male). The area under the curve score of the PWL model to predict DoT at 3, 6, and 12 months was 0.61, 0.64, and 0.66, respectively. Based on the similarity of coefficients of regression models, samples were categorized into 2 clusters (clusters A and B) at DoT of 3 months, 3 clusters (clusters A, B, and C) at 6 months, and 12 months (clusters A, B, and C). Cluster B versus cluster A (at 3 months) and cluster C versus cluster A and B (at 6 and 12 months) had a significantly (P<.01) higher pretreatment Charlson Comorbidity Index. They also showed a lower median of prediction probability. At 3 months in cluster B and at 6 and 12 months in cluster C, the use of immunomodulatory drugs for MM treatment was significantly higher in patients who met predicted DoT at each threshold versus those who did not. Additionally, the use of aspirin was significantly higher in cluster B and cluster C at 3 and 6 months, respectively. Conclusions: Applying ML techniques using the PWL model yielded efficient results to understand trends associated with treatment and characteristics of Japanese patients with MM whose DoT were shortened. The study demonstrated that patients’ disease status and management-related factors, including use of immunomodulatory drugs and management of thromboprophylaxis, may be associated with DoT length.
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e75586
Open AccessAssessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database
Background: With the availability of newer therapies, the duration of therapy (DoT) shortens with each increasing line of treatment in Japanese patients with multiple myeloma (MM). Objective: This study aimed to identify factors that shorten DoT in patients with MM using a machine learning (ML) procedure from the Medical Data Vision (MDV) database. Methods: This nationwide, retrospective observational real-world study was conducted using anonymized patient data from the MDV claims database from 2003 to 2022. Patients (≥18 y) with transplant-ineligible newly diagnosed MM (continued first line therapy), or relapsed or refractory MM (continued second or third line therapies) were included. To identify important predictive factors, an explainable deep learning model was created using 647 extracted variables (continuous, binary, and nominal categorical) from the MDV database, and the extracted data were used to train ML algorithms to build point-wise linear (PWL) models for predicting DoT. Predictive performance of the PWL model was compared with the elastic net (regularized logistic regression) and the extreme gradient boosting models, and calculated by area under the curve and evaluated by 10-fold double cross-validation. A clustering analysis (k-means method) of 4848 individual samples assessed the relationship between each sample and DoT (3, 6, and 12 months). The characteristics of clusters and sample features belonging to each cluster during and after treatment were studied. Results: Overall, 2762 (4848 individual samples) patients were evaluated (mean age 69.6, SD 11.8 years; 1450/2762, 52.5% male). The area under the curve score of the PWL model to predict DoT at 3, 6, and 12 months was 0.61, 0.64, and 0.66, respectively. Based on the similarity of coefficients of regression models, samples were categorized into 2 clusters (clusters A and B) at DoT of 3 months, 3 clusters (clusters A, B, and C) at 6 months, and 12 months (clusters A, B, and C). Cluster B versus cluster A (at 3 months) and cluster C versus cluster A and B (at 6 and 12 months) had a significantly (P<.01) higher pretreatment Charlson Comorbidity Index. They also showed a lower median of prediction probability. At 3 months in cluster B and at 6 and 12 months in cluster C, the use of immunomodulatory drugs for MM treatment was significantly higher in patients who met predicted DoT at each threshold versus those who did not. Additionally, the use of aspirin was significantly higher in cluster B and cluster C at 3 and 6 months, respectively. Conclusions: Applying ML techniques using the PWL model yielded efficient results to understand trends associated with treatment and characteristics of Japanese patients with MM whose DoT were shortened. The study demonstrated that patients’ disease status and management-related factors, including use of immunomodulatory drugs and management of thromboprophylaxis, may be associated with DoT length.
- Top Cited PapersOpen Access
- 20 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (3) , 164-175
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
PURPOSE: Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency. METHODS: The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744 ) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed–progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (–5 ), and safety. RESULTS: Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136]; P = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade ≥3 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone. CONCLUSION: The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.
- 20 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (3) , 164-175
Top Cited PapersOpen AccessVenetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
PURPOSE: Venetoclax, an oral BCL-2 inhibitor, has efficacy in t(11;14)-positive relapsed/refractory multiple myeloma (RRMM), which is enhanced by dexamethasone, which promotes BCL-2 dependency. METHODS: The randomized, open-label, phase III CANOVA study (ClinicalTrials.gov identifier: NCT03539744 ) enrolled adults with t(11;14)-positive RRMM who had received ≥2 previous lines of therapy. Patients were randomly assigned (1:1) to venetoclax-dexamethasone or pomalidomide-dexamethasone until progression or intolerable toxicity. The primary end point was independent review committee assessed–progression-free survival (PFS) in the intention-to-treat population analyzed by stratified log-rank test (two-sided type I error rate, α = .05), with hazard ratio (HR) and 95% CI estimated by stratified Cox proportional hazard model. Secondary end points included response rates, overall survival (OS), minimal residual disease (MRD) negativity rate (–5 ), and safety. RESULTS: Overall, 263 patients were randomly assigned (venetoclax-dexamethasone, n = 133; pomalidomide-dexamethasone, n = 130). Median PFS was 9.9 months (95% CI, 6.9 to 12.6) with venetoclax-dexamethasone versus 5.8 months (95% CI, 3.8 to 9.2) with pomalidomide-dexamethasone (HR, 0.823 [95% CI, 0.596 to 1.136]; P = .24). Overall response and very good partial response or better rates were 62% and 39%, respectively, with venetoclax-dexamethasone versus 35% and 14% with pomalidomide-dexamethasone. MRD negativity rate was 8% with venetoclax-dexamethasone and 0% with pomalidomide-dexamethasone. Median OS was 32.4 months (95% CI, 26.4 to 40.7) with venetoclax-dexamethasone and 26.9 months (95% CI, 20.4 to 38.9) with pomalidomide-dexamethasone (HR, 0.856 [95% CI, 0.612 to 1.197]). Grade ≥3 treatment-emergent adverse event rates were 67% with venetoclax-dexamethasone versus 83% with pomalidomide-dexamethasone. There were 16 (12%) treatment-emergent deaths with venetoclax-dexamethasone versus 8 (6%) with pomalidomide-dexamethasone. CONCLUSION: The primary end point of PFS was not met. PFS and OS were numerically longer with venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM. Consistent with previous studies, infections were associated with venetoclax-dexamethasone; no new safety signals were observed.
- Open Access
- 22 December 2025
- Published by Springer Nature in Research Square
Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: A single arm, phase 3 trial, JCOG0907
This single-arm, phase 3 trial by the Japan Clinical Oncology Group evaluated the strategy of upfront allogeneic hematopoietic stem cell transplantation (allo-HSCT) after intensive chemotherapy for untreated aggressive adult T-cell leukemia-lymphoma (ATL). Patients ≤ 65 years old with aggressive ATL were eligible. The protocol-treatment was VCAP-AMP-VECP as induction-chemotherapy followed by allo-HSCT in first remission. Between 2010 and 2020, 110 patients were enrolled. Among all 92 transplantations, 41 under per-protocol (study transplantation) and 51 under off-protocol received allo-HSCT. The primary endpoint was met with 3-year OS of 44.0% (90% CI, 36.0–51.6 > 25.0). The median survival time of the study transplantation and all transplantation was 3.0 (95% CI, 1.5–5.8) and 2.5 years (95% CI, 1.4–4.8), respectively. Multivariable analysis with a time-dependent covariate for transplantation revealed that the hazard ratio for OS of study transplantation was 0.915 (95% CI, 0.554–1.512). In study transplantation, the rate of treatment-related death (TRD) in related and unrelated transplantation was 16.7% and 20.7%, respectively. Thirty-four deaths due to disease progression (PD) were observed. Upfront allo-HSCT can be recommended for aggressive ATL despite a relatively high rate of PD and TRD. However, the survival benefit of study transplantation remains unclear considering the immortal bias.
- 22 December 2025
- Published by Springer Nature in Research Square
Open AccessUpfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: A single arm, phase 3 trial, JCOG0907
This single-arm, phase 3 trial by the Japan Clinical Oncology Group evaluated the strategy of upfront allogeneic hematopoietic stem cell transplantation (allo-HSCT) after intensive chemotherapy for untreated aggressive adult T-cell leukemia-lymphoma (ATL). Patients ≤ 65 years old with aggressive ATL were eligible. The protocol-treatment was VCAP-AMP-VECP as induction-chemotherapy followed by allo-HSCT in first remission. Between 2010 and 2020, 110 patients were enrolled. Among all 92 transplantations, 41 under per-protocol (study transplantation) and 51 under off-protocol received allo-HSCT. The primary endpoint was met with 3-year OS of 44.0% (90% CI, 36.0–51.6 > 25.0). The median survival time of the study transplantation and all transplantation was 3.0 (95% CI, 1.5–5.8) and 2.5 years (95% CI, 1.4–4.8), respectively. Multivariable analysis with a time-dependent covariate for transplantation revealed that the hazard ratio for OS of study transplantation was 0.915 (95% CI, 0.554–1.512). In study transplantation, the rate of treatment-related death (TRD) in related and unrelated transplantation was 16.7% and 20.7%, respectively. Thirty-four deaths due to disease progression (PD) were observed. Upfront allo-HSCT can be recommended for aggressive ATL despite a relatively high rate of PD and TRD. However, the survival benefit of study transplantation remains unclear considering the immortal bias.
- Open Access
- 8 December 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (1) , 147-149
Correction: JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM)
- 8 December 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (1) , 147-149
Open AccessCorrection: JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM)
- Open Access
- 4 December 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma
TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple myeloma (NDMM) that demonstrated improved median progression-free survival (PFS) for ixazomib vs placebo. We present the final overall survival (OS) analyses for each study separately. In both studies, eligible patients were randomized 3:2 to receive ixazomib maintenance (3 mg [cycles 1–4], 4 mg [from cycle 5 if tolerated]) or matching placebo for ≤26 cycles, or until progressive disease/unacceptable toxicity. At median follow-up of approximately 8 years (TOURMALINE-MM3) and 5 years (TOURMALINE-MM4), median OS was not reached in either arm in MM3 (hazard ratio [HR], 1.025; 95% confidence interval [CI], 0.789–1.332; p = 0.850), and was 64.8 (ixazomib) vs 69.5 (placebo) months in MM4 (HR, 1.090; 95% CI, 0.861–1.381; p = 0.473). No new safety signals were identified in either study; incidence of new primary malignancies was low. Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance and placebo in patients with NDMM. The growing number of available, highly effective salvage treatments with novel mechanisms of action make demonstrating an OS advantage in front-line myeloma studies increasingly challenging.
- 4 December 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessFinal OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma
TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple myeloma (NDMM) that demonstrated improved median progression-free survival (PFS) for ixazomib vs placebo. We present the final overall survival (OS) analyses for each study separately. In both studies, eligible patients were randomized 3:2 to receive ixazomib maintenance (3 mg [cycles 1–4], 4 mg [from cycle 5 if tolerated]) or matching placebo for ≤26 cycles, or until progressive disease/unacceptable toxicity. At median follow-up of approximately 8 years (TOURMALINE-MM3) and 5 years (TOURMALINE-MM4), median OS was not reached in either arm in MM3 (hazard ratio [HR], 1.025; 95% confidence interval [CI], 0.789–1.332; p = 0.850), and was 64.8 (ixazomib) vs 69.5 (placebo) months in MM4 (HR, 1.090; 95% CI, 0.861–1.381; p = 0.473). No new safety signals were identified in either study; incidence of new primary malignancies was low. Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance and placebo in patients with NDMM. The growing number of available, highly effective salvage treatments with novel mechanisms of action make demonstrating an OS advantage in front-line myeloma studies increasingly challenging.
- Open Access
- 26 November 2025
- Published by Wiley in Cancer Science
- Vol. 117 (2) , 325-334
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma
Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to kynurenine (Kyn), plays an immunosuppressive role in the TME. We previously reported that a high Kyn/Trp ratio was associated with poor prognosis in lenalidomide‐treated refractory/relapsed MM patients and that IDO expression in stromal cells was upregulated by co‐culture with MM cells. Here, we analyzed the mechanism through which MM cells upregulate IDO in stromal cells and aimed to identify compounds that inhibit IDO upregulation. Two MM cell lines, XG‐7 and IM‐9, upregulated IDO in stromal cells both directly and indirectly. These two MM cell lines also upregulated programmed cell death ligand 1 (PD‐L1) in stromal cells, which was closely related to IDO upregulation. RNA sequencing analysis revealed that cytokine signaling pathways were commonly upregulated in stromal cells co‐cultured with these two MM cell lines. In stromal cells co‐cultured with MM cells, signal transducer and activator of transcription 1 (STAT1) and nuclear factor‐κB (NF‐κB) p65 was phosphorylated, and interferon regulatory factor 1 (IRF1), which binds to the IDO promoter region, was strongly upregulated. This IDO and IRF1 upregulation were abolished by Janus kinase (JAK) inhibitor. In addition, stromal cells with knockout of IRF1 showed little upregulation of IDO when co‐cultured with MM cells. These results suggest that the JAK–STAT1–NF‐κB–IRF1 signaling pathway may be involved in IDO upregulation. JAK inhibitors may improve the TME in MM and positively influence immunotherapy outcomes.
- 26 November 2025
- Published by Wiley in Cancer Science
- Vol. 117 (2) , 325-334
Open AccessTargeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma
Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to kynurenine (Kyn), plays an immunosuppressive role in the TME. We previously reported that a high Kyn/Trp ratio was associated with poor prognosis in lenalidomide‐treated refractory/relapsed MM patients and that IDO expression in stromal cells was upregulated by co‐culture with MM cells. Here, we analyzed the mechanism through which MM cells upregulate IDO in stromal cells and aimed to identify compounds that inhibit IDO upregulation. Two MM cell lines, XG‐7 and IM‐9, upregulated IDO in stromal cells both directly and indirectly. These two MM cell lines also upregulated programmed cell death ligand 1 (PD‐L1) in stromal cells, which was closely related to IDO upregulation. RNA sequencing analysis revealed that cytokine signaling pathways were commonly upregulated in stromal cells co‐cultured with these two MM cell lines. In stromal cells co‐cultured with MM cells, signal transducer and activator of transcription 1 (STAT1) and nuclear factor‐κB (NF‐κB) p65 was phosphorylated, and interferon regulatory factor 1 (IRF1), which binds to the IDO promoter region, was strongly upregulated. This IDO and IRF1 upregulation were abolished by Janus kinase (JAK) inhibitor. In addition, stromal cells with knockout of IRF1 showed little upregulation of IDO when co‐cultured with MM cells. These results suggest that the JAK–STAT1–NF‐κB–IRF1 signaling pathway may be involved in IDO upregulation. JAK inhibitors may improve the TME in MM and positively influence immunotherapy outcomes.